Edition:
India

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

565.45INR
3:52pm IST
Change (% chg)

Rs21.30 (+3.91%)
Prev Close
Rs544.15
Open
Rs560.00
Day's High
Rs567.00
Day's Low
Rs550.40
Volume
1,586,746
Avg. Vol
2,288,712
52-wk High
Rs678.45
52-wk Low
Rs483.75

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.52
Market Cap(Mil.): Rs438,423.41
Shares Outstanding(Mil.): 805.70
Dividend: 3.00
Yield (%): 0.55

Financials

  CIPL.NS Industry Sector
P/E (TTM): 32.79 54.03 55.51
EPS (TTM): 16.60 -- --
ROI: -- 11.89 11.59
ROE: -- 13.19 16.33

BUZZ-India's Cipla rises after U.S. FDA closes inspection at Goa unit

** Shares of generic drugmaker Cipla Ltd rise as much as 3.41 pct to 538.75 rupees, their highest in a fortnight

05 Apr 2019

Cipla third-quarter profit falls as lean India sales, tax cost weigh

Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.

06 Feb 2019

UPDATE 1-India's Cipla Q3 profit falls as lean India sales, tax cost weigh

Feb 6 Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.

06 Feb 2019

Indian shares end higher for fifth session

Feb 6 Indian shares ended higher for a fifth straight session on Wednesday, with gains across most verticals, as investor sentiment was buoyed by a slew of upbeat quarterly results ahead of a key central bank policy meet which concludes on Thursday.

06 Feb 2019

India's Cipla Q3 profit falls, lags estimate

Feb 6 Cipla Ltd, India's second-biggest generic drugmaker by market capitalisation, reported a 17.1 percent fall in third-quarter profit on Wednesday, hurt by higher tax expenses.

06 Feb 2019

Earnings vs. Estimates